Blood · 2021 · 81 citations · 31 references
Life SciencesHematologyImmunologyCancer ImmunologyImmunogeneticsImmunopathologyB Cell ActivationB Cell BiologyB Cell DevelopmentB Cell RegulationB-cell ResponsesMultiple MyelomaB-cell SignaturesMyeloma Pathogenesis
Venetoclax is a highly potent, selective BCL2 inhibitor capable of inducing apoptosis in cells dependent on BCL2 for survival. Most myeloma is MCL1-dependent; however, a subset of myeloma enriched for translocation t(11;14) is codependent on BCL2 and thus sensitive to venetoclax. The biology underlying this heterogeneity remains poorly understood. We show that knockdown of cyclin D1 does not induce resistance to venetoclax, arguing against a direct role for cyclin D1 in venetoclax sensitivity. To identify other factors contributing to venetoclax response, we studied a panel of 31 myeloma cell lines and 25 patient samples tested for venetoclax sensitivity. In cell lines, we corroborated our previous observation that BIM binding to BCL2 correlates with venetoclax response and further showed that knockout of BIM results in decreased venetoclax sensitivity. RNA-sequencing analysis identified expression of B-cell genes as enriched in venetoclax-sensitive myeloma, although no single gene consistently delineated sensitive and resistant cells. However, a panel of cell surface makers correlated well with ex vivo prediction of venetoclax response in 21 patient samples and may serve as a biomarker independent of t(11;14). Assay for transposase-accessible chromatin sequencing of myeloma cell lines also identified an epigenetic program in venetoclax-sensitive cells that was more similar to B cells than that of venetoclax-resistant cells, as well as enrichment for basic leucine zipper domain-binding motifs such as BATF. Together, these data indicate that remnants of B-cell biology are associated with BCL2 dependency and point to novel biomarkers of venetoclax-sensitive myeloma independent of t(11;14).
31
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.9K citations · Full text
Medicine, Cancer Biology, Oncology +14
The molecular classification of multiple myeloma
Fenghuang Zhan, Yongsheng Huang, Simona Colla et al. · Blood · 2006 · 1.1K citations · Full text
Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities
Kendall R Sanson, Ruth E. Hanna, Mudra Hegde et al. · Nature Communications · 2018 · 1.1K citations · Full text
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1.1K citations
Medicine, Oncology, Pharmacology +11